Headlines about Innoviva (NASDAQ:INVA) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Innoviva earned a news sentiment score of 0.23 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.431760024037 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the media headlines that may have effected Accern’s rankings:

Shares of Innoviva (NASDAQ:INVA) opened at 12.47 on Friday. The firm’s 50-day moving average is $12.94 and its 200-day moving average is $12.43. Innoviva has a 12-month low of $8.67 and a 12-month high of $14.55. The company has a market capitalization of $1.36 billion, a price-to-earnings ratio of 15.69 and a beta of 2.56.

Innoviva (NASDAQ:INVA) last posted its quarterly earnings results on Wednesday, July 26th. The biotechnology company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.28 by $0.02. The firm had revenue of $58.60 million for the quarter, compared to the consensus estimate of $50.53 million. Innoviva had a net margin of 52.56% and a negative return on equity of 27.37%. The business’s revenue was up 80.3% compared to the same quarter last year. During the same period last year, the firm posted $0.13 earnings per share. On average, equities analysts predict that Innoviva will post $1.14 EPS for the current year.

A number of equities research analysts have weighed in on the stock. Zacks Investment Research raised shares of Innoviva from a “hold” rating to a “strong-buy” rating and set a $16.00 target price on the stock in a report on Monday, July 31st. Cowen and Company set a $16.00 target price on shares of Innoviva and gave the stock a “buy” rating in a report on Friday, July 28th. Stifel Nicolaus reissued a “hold” rating and set a $15.00 target price on shares of Innoviva in a report on Friday, July 28th. Robert W. Baird reissued a “neutral” rating and set a $13.00 target price (up from $11.00) on shares of Innoviva in a report on Thursday, July 27th. Finally, ValuEngine lowered shares of Innoviva from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Three analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $15.00.

ILLEGAL ACTIVITY WARNING: This article was reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/12/innoviva-nasdaqinva-receiving-somewhat-positive-news-coverage-analysis-finds.html.

In other Innoviva news, VP Theodore J. Jr. Witek sold 7,815 shares of Innoviva stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $12.01, for a total transaction of $93,858.15. Following the transaction, the vice president now directly owns 251,968 shares of the company’s stock, valued at $3,026,135.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.60% of the company’s stock.

About Innoviva

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Receive News & Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related companies with MarketBeat.com's FREE daily email newsletter.